There are 116 resources available
Who should we treat? Optimizing the impact of RLT in patients with metastatic castration resistant prostate cancer
Presenter: Kim Nguyen Chi, Matthias Eiber, Joan Carles Galceran, Jochen Walz
Session: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?
Resources:
Webcast
PI3Ki: An evolving drug class with an exciting future
Presenter: Carlos Barrios
Session: F. Hoffmann - La Roche Ltd - How can we PI3K the right treatment for every patient with HR+ breast cancer?
Resources:
Webcast
Where are we going? Discussing the future of RLT in patients with advanced prostate cancer
Presenter: Kim Nguyen Chi, Matthias Eiber, Joan Carles Galceran, Jochen Walz
Session: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?
Resources:
Webcast
Q&A
Presenter: Carlos Barrios, Komal Jhaveri, Kevin Kalinsky
Session: F. Hoffmann - La Roche Ltd - How can we PI3K the right treatment for every patient with HR+ breast cancer?
Resources:
Webcast
Closing remarks
Presenter: Kim Nguyen Chi
Session: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?
Resources:
Webcast
Close
Presenter: Kevin Kalinsky
Session: F. Hoffmann - La Roche Ltd - How can we PI3K the right treatment for every patient with HR+ breast cancer?
Resources:
Webcast
Welcome and Introductions
Presenter: Josep Tabernero
Session: Pierre Fabre Laboratories - Precision oncology for BRAF mutant cancers
Resources:
Webcast
Welcome and introduction
Presenter: Richard Finn
Session: F. Hoffmann - La Roche Ltd - Pioneering GI cancer treatments and maximising outcomes for patients with HCC
Resources:
Webcast
Welcome and Introduction
Presenter: Javier Cortés
Session: Medscape Global Oncology - Redefining Care for HR-Positive Metastatic Breast Cancer: How to Navigate Critical Decision Points
Resources:
Webcast
Targeting oncogenic BRAF
Presenter: Reinhard Dummer
Session: Pierre Fabre Laboratories - Precision oncology for BRAF mutant cancers
Resources:
Webcast